Continuous positive airway pressure (CPAP) therapy has been the gold standard therapy for moderate‐to‐severe obstructive sleep apnoea (OSA) for several decades.1 Therapeutic success for CPAP therapy is generally defined as a reduction in the apnoea–hypopnoea index (AHI) to below 5 events/h with concurrent improvement in symptoms (including daytime sleepiness, snoring and quality of life) and satisfactory long‐term adherence. This is achievable in many patients, yet approximately 50% of patients either refuse CPAP therapy or are non‐adherent.2 Others are compliant with therapy but persistently demonstrate a residual AHI ≥5 events/h indicating suboptimal control. To date, there has been limited epidemiological or mechanistic research regarding patients with a residual AHI ≥5 events/h on CPAP therapy.
- continuous positive airway pressure
- residual apnoeic events
- sleep apnoea